Protease inhibitor-associated hyperglycaemia [5]

Lancet

Volumn 350, Issue 9079, 1997, Pages 713-714

  Dubé, Michael P ^a   Johnson, Deborah L ^b   Currier, Judith S ^b   Leedom, John M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; CLINICAL ARTICLE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LETTER; MALE; PRIORITY JOURNAL;

EID: 0030818613     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63513-1     Document Type: Article

References (2)

1. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus, FDA Public Health Advisory, June 11, 1997.
2. Norvir package insert. Abbott Laboratories, North Chicago, IL, USA. May, 1996.